AC Immune SA NASDAQ:ACIU

Founder-led company

AC Immune SA stock price today

$2.2
-0.52
-19.41%
Financial Health
0
1
2
3
4
5
6
7
8
9

AC Immune SA stock price monthly change

-25.00%
month

AC Immune SA stock price quarterly change

-25.00%
quarter

AC Immune SA stock price yearly change

-45.07%
year

AC Immune SA key metrics

Market Cap
264.15M
Enterprise value
150.93M
P/E
-2.31
EV/Sales
38.35
EV/EBITDA
-2.21
Price/Sales
42.93
Price/Book
0.99
PEG ratio
-0.18
EPS
-0.61
Revenue
N/A
EBITDA
-53.92M
Income
-54.58M
Revenue Q/Q
N/A
Revenue Y/Y
276.13%
Profit margin
-1798.12%
Oper. margin
-1800.48%
Gross margin
0%
EBIT margin
-1800.48%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

AC Immune SA stock price history

AC Immune SA stock forecast

AC Immune SA financial statements

AC Immune SA (NASDAQ:ACIU): Profit margin
Jun 2023 0 -16.83M
Sep 2023 0 -15.14M
Dec 2023 14.80M -4.74M -32.05%
Mar 2024 0 -17.86M
AC Immune SA (NASDAQ:ACIU): Analyst Estimates
Sep 2023 0 -15.14M
Dec 2023 14.80M -4.74M -32.05%
Mar 2024 0 -17.86M
Dec 2025 171.94M 0
  • Analysts Price target

  • Financials & Ratios estimates

AC Immune SA (NASDAQ:ACIU): Earnings per share (EPS)
2023-04-27 -0.25 -0.25
AC Immune SA (NASDAQ:ACIU): Debt to assets
Jun 2023 156228000 16.9M 10.82%
Sep 2023 142986000 17.32M 12.11%
Dec 2023 182814000 22.17M 12.13%
Mar 2024 167281000 22.6M 13.51%
AC Immune SA (NASDAQ:ACIU): Cash Flow
Jun 2023 -14.11M -5.15M 1.91M
Sep 2023 -13.3M 4.72M 448K
Dec 2023 -16.19M 23.28M 41.02M
Mar 2024 1.02M -23.56M -688K

AC Immune SA alternative data

AC Immune SA (NASDAQ:ACIU): Employee count
Aug 2023 126
Sep 2023 126
Oct 2023 126
Nov 2023 126
Dec 2023 126
Jan 2024 126
Feb 2024 126
Mar 2024 133
Apr 2024 133
May 2024 133
Jun 2024 133
Jul 2024 133

AC Immune SA other data

19.07% -1.86%
of ACIU is owned by hedge funds
14.29M -755.70K
shares is hold by hedge funds
Patent
Grant
Filling date: 5 Jun 2020 Issue date: 30 Aug 2022
Application
Filling date: 20 May 2020 Issue date: 21 Jul 2022
Grant
Filling date: 9 Oct 2020 Issue date: 7 Jun 2022
Application
Filling date: 29 Jan 2020 Issue date: 28 Apr 2022
Grant
Filling date: 22 Jan 2019 Issue date: 19 Apr 2022
Application
Filling date: 4 Jan 2019 Issue date: 27 Jan 2022
Application
Filling date: 19 Aug 2021 Issue date: 16 Dec 2021
Application
Filling date: 3 Dec 2020 Issue date: 28 Oct 2021
Grant
Filling date: 24 Oct 2018 Issue date: 21 Sep 2021
Application
Filling date: 30 May 2019 Issue date: 2 Sep 2021
Insider Compensation
Dr. Andrea Pfeifer (1957) Co-Founder, Chief Executive Officer & Director
$1,140,000
Thursday, 14 November 2024
benzinga.com
Tuesday, 6 August 2024
zacks.com
Wednesday, 31 July 2024
globenewswire.com
Friday, 26 July 2024
seekingalpha.com
Thursday, 25 July 2024
globenewswire.com
Tuesday, 28 May 2024
globenewswire.com
Monday, 13 May 2024
Market Watch
InvestorPlace
Tuesday, 30 January 2024
Zacks Investment Research
Monday, 8 January 2024
Zacks Investment Research
Wednesday, 3 January 2024
Zacks Investment Research
Monday, 11 December 2023
Zacks Investment Research
Tuesday, 5 December 2023
Zacks Investment Research
Tuesday, 28 November 2023
InvestorPlace
Thursday, 9 November 2023
Zacks Investment Research
Tuesday, 7 November 2023
GlobeNewsWire
Tuesday, 24 October 2023
Zacks Investment Research
Friday, 20 October 2023
Zacks Investment Research
Thursday, 5 October 2023
GlobeNewsWire
Tuesday, 5 September 2023
Zacks Investment Research
GlobeNewsWire
Friday, 4 August 2023
Zacks Investment Research
Friday, 28 July 2023
GlobeNewsWire
Friday, 30 June 2023
The Motley Fool
Wednesday, 28 June 2023
PennyStocks
Tuesday, 27 June 2023
Market Watch
Monday, 20 March 2023
GlobeNewsWire
Saturday, 18 March 2023
Seeking Alpha
Wednesday, 8 March 2023
GlobeNewsWire
Thursday, 2 February 2023
GlobeNewsWire
  • What's the price of AC Immune SA stock today?

    One share of AC Immune SA stock can currently be purchased for approximately $2.2.

  • When is AC Immune SA's next earnings date?

    Unfortunately, AC Immune SA's (ACIU) next earnings date is currently unknown.

  • Does AC Immune SA pay dividends?

    No, AC Immune SA does not pay dividends.

  • How much money does AC Immune SA make?

    AC Immune SA has a market capitalization of 264.15M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 276.14% to 14.8M US dollars. AC Immune SA made a loss 54.23M US dollars in net income (profit) last year or -$0.25 on an earnings per share basis.

  • What is AC Immune SA's stock symbol?

    AC Immune SA is traded on the NASDAQ under the ticker symbol "ACIU".

  • What is AC Immune SA's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of AC Immune SA?

    Shares of AC Immune SA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are AC Immune SA's key executives?

    AC Immune SA's management team includes the following people:

    • Dr. Andrea Pfeifer Co-Founder, Chief Executive Officer & Director(age: 68, pay: $1,140,000)
  • Is AC Immune SA founder-led company?

    Yes, AC Immune SA is a company led by its founder Dr. Andrea Pfeifer.

  • How many employees does AC Immune SA have?

    As Jul 2024, AC Immune SA employs 133 workers.

  • When AC Immune SA went public?

    AC Immune SA is publicly traded company for more then 8 years since IPO on 23 Sep 2016.

  • What is AC Immune SA's official website?

    The official website for AC Immune SA is acimmune.com.

  • How can i contact AC Immune SA?

    AC Immune SA can be reached via phone at +41 21 345 91 21.

AC Immune SA company profile:

AC Immune SA

acimmune.com
Exchange:

NASDAQ

Full time employees:

133

Industry:

Biotechnology

Sector:

Healthcare

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Building B
Lausanne, 1015

CIK: 0001651625
ISIN: CH0329023102
CUSIP: H00263105